Market Insights Health Hospitals Inpatient Care

Neoplasm Treatment - Iraq

Iraq

The Neoplasm Treatment market in Iraq is anticipated to witness substantial growth in the coming years.
According to projections, the revenue in this market is expected to reach US$0.59bn by 2024.
Furthermore, it is estimated that the market will experience a steady annual growth rate of 4.06% (CAGR 2024-2029), leading to a market volume of US$0.72bn by 2029.
In terms of global comparison, United States is poised to generate the highest revenue in the Neoplasm Treatment market.
It is anticipated that United States will generate a staggering US$90.56bn in revenue by 2024.
Iraq is witnessing a surge in the adoption of advanced neoplasm treatment technologies, bolstering the country's healthcare sector.

Key regions: Europe, Canada, Brazil, United States, United Kingdom

Market

Region

Region comparison

Currency

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on revenue received by hospitals from public or private sources, allocated to the country where the money is spent, including VAT if applicable.

Modeling approach / Market size:

Market sizes are determined by a bottom-up approach, based on a specific rationale for each market market. Next, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, public health spend, and GDP. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level.